Effects of Viral Infections Like COVID-19 on Head and Neck Cancers: The Role of Neutrophil-Lymphocyte Counts and Ratios

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jul 8

PMID 38975442

Authors

Sunayana R Sarkar

Hitesh R Singhavi

Abhishek Das

Ipsita Dhal

Shreya Shukla

Sambit S Nanda

Aseem Mishra

Komal Lamba

Anamika Mishra

Affiliations

Soon will be listed here.

Abstract

Background: Over the last three years, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a global impact. COVID-19 has led to diagnostic and treatment delays in head and neck squamous cell cancers (HNSCCs). Both cancer and COVID-19 trigger systemic inflammatory responses that can result in cytokine storms, creating a favorable tumor microenvironment that supports tumor growth. Various studies have shown a positive association between increasing neutrophil-to-lymphocyte ratio (NLR) and disease severity in COVID-19. Studies have also shown that high NLR is associated with poor survival outcomes in cancer patients. Our aim is to investigate whether an increased NLR is linked to rapid tumor progression in patients with HNSCC who have also been affected by infections like COVID-19 in the pre-operative period.

Methods: This was a retrospective analysis of patients of HNSCC who were scheduled for surgery and had contracted COVID-19 in their pre-operative period between April 2021 and May 2021. The study analyzed pre- and post-COVID NLR in relation to disease progression in HNSCC. Statistical analysis was presented as an interquartile range and numbered with the percentage. Statistical Package for the Social Sciences (IBM SPSS Statistics for Windows, IBM Corp., Version 26.0, Armonk, NY) was utilized for the analysis.

Results: We evaluated 200 operable cases of which 38/200 (20%) patients with HNSCC were COVID-19 positive. Out of those COVID-19-positive patients, 27/38 (71%) patients got operated. Around, 11/38 (28.9%) patients were inoperable. And, 14/27 (53.8%) operated patients also had a change in treatment plan. The mean duration from the joint clinic treatment plan to the date of surgery was 25.18 days. Patients who had contracted COVID-19 and had a change in their treatment plan due to disease progression exhibited mean NLR values of 3.84 (pre-COVID) and 11.11 (post-COVID), with respective medians of 3.04 and 10.50. These differences showed a statistically significant p-value of 0.000. In contrast, patients who had no change in treatment plan displayed mean NLR values of 4.51 (pre-COVID) and 9.70 (post-COVID), with respective medians of 3.47 and 3.42, resulting in with a non-significant p-value of 0.082.

Conclusion: This is a one-of-its-kind study that has evaluated the role of elevated NLR in patients with a COVID-19 virus infection and its relationship with the clinical progression of the disease. The findings suggest that elevated NLR in patients with HNSCC, along with concurrent SARS-CoV2 infection, may contribute to accelerated disease progression with an increase in tumor burden and nodal metastasis.

References

Jensen A, Nellemann H, Overgaard J . Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol. 2007; 84(1):5-10. DOI: 10.1016/j.radonc.2007.04.001. View

Perri F, Crispo A, Ionna F, Muto P, Caponigro F, Longo F . Patients affected by squamous cell carcinoma of the head and neck: A population particularly prone to developing severe forms of COVID-19. Exp Ther Med. 2021; 22(5):1298. PMC: 8461515. DOI: 10.3892/etm.2021.10733. View

Hao S, Andersen M, Yu H . Detection of immune suppressive neutrophils in peripheral blood samples of cancer patients. Am J Blood Res. 2013; 3(3):239-45. PMC: 3755524. View

Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R . The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020; 11:1446. PMC: 7308649. DOI: 10.3389/fimmu.2020.01446. View

Ozaki A, Nomura S, Leppold C, Tsubokura M, Tanimoto T, Yokota T . Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study. BMC Cancer. 2017; 17(1):423. PMC: 5477136. DOI: 10.1186/s12885-017-3412-4. View

Fridlender Z, Albelda S, Granot Z . Promoting metastasis: neutrophils and T cells join forces. Cell Res. 2015; 25(7):765-6. PMC: 4493274. DOI: 10.1038/cr.2015.62. View

Templeton A, McNamara M, Seruga B, Vera-Badillo F, Aneja P, Ocana A . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):dju124. DOI: 10.1093/jnci/dju124. View

Uribe-Querol E, Rosales C . Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res. 2016; 2015:983698. PMC: 4706937. DOI: 10.1155/2015/983698. View

Chen M, Tsai M, Chen W, Chen P . Predictive Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma. J Clin Med. 2018; 7(10). PMC: 6210359. DOI: 10.3390/jcm7100294. View

10.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y . Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15):762-768. PMC: 7108125. DOI: 10.1093/cid/ciaa248. View

11.

Goodyear M, Krleza-Jeric K, Lemmens T . The Declaration of Helsinki. BMJ. 2007; 335(7621):624-5. PMC: 1995496. DOI: 10.1136/bmj.39339.610000.BE. View

12.

Shrikhande S, Pai P, Bhandare M, Bakshi G, Chaukar D, Chaturvedi P . Outcomes of Elective Major Cancer Surgery During COVID 19 at Tata Memorial Centre: Implications for Cancer Care Policy. Ann Surg. 2020; 272(3):e249-e252. PMC: 7299113. DOI: 10.1097/SLA.0000000000004116. View

13.

Pandrowala S, Ramraj D, Shankar R, Chopra S, Das A, Mishra A . Impact of preoperative COVID infection on the outcomes of planned curative-intent cancer surgeries in the second wave of the pandemic from a tertiary care center in India. J Surg Oncol. 2021; 125(2):107-112. PMC: 8662274. DOI: 10.1002/jso.26697. View

14.

Graboyes E, Kompelli A, Neskey D, Brennan E, Nguyen S, Sterba K . Association of Treatment Delays With Survival for Patients With Head and Neck Cancer: A Systematic Review. JAMA Otolaryngol Head Neck Surg. 2018; 145(2):166-177. PMC: 6494704. DOI: 10.1001/jamaoto.2018.2716. View